Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands it
Post# of 420
(Total Views: 227)
Posted On: 04/29/2022 3:06:15 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH
- Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugs
- This becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S.
- It adds to the company’s growing patent portfolio, which also consists of ~50 pending patents worldwide
- Over the 2022 calendar year, the company seeks to also pursue regulatory and commercial advancement
In 2016, Lexaria Bioscience (NASDAQ: LEXX) received its first United States patent grant and over the years, the company has been aggressive at broadening its patent suite, a move which it has attributed to refining the patent claims via further US provisional and utility patent filings. More patents mean more intellectual property and enhanced ability to pursue regulatory and commercial progress.
As of March 2022, Lexaria had 24 patents, having been granted its latest one in Australia, titled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof” (https://nnw.fm/CYJnV ).
In what marks another significant milestone for Lexaria, it has announced receiving its first-ever patent for the use of DehydraTECH(TM) technology in the enhanced delivery of antiviral drugs. Patent 11,311,559, titled “Compositions and Methods for Enhanced Delivery of Antiviral Agents,” becomes the 10th granted in the U.S.
“This will be our 25th patent granted worldwide and another validation of the versatility of our DehydraTECH drug delivery technology,” noted Lexaria’s Chief Executive Officer (“CEO”), Chris Bunka (https://nnw.fm/F5dID ).
Lexaria had earlier announced and demonstrated how effective remdesivir and ebastine processed with DehydraTECH were against inhibiting COVID-19/SARS-CoV-2. It also separately proved that antiviral drugs processed with DehydraTECH reached peak blood concentration levels that were double those of non-DehydraTECH-processed alternatives. In addition, the company showed that the overall volumes of drugs delivered into the bloodstream were up to triple that of non-DehydraTECH-processed variants.
Lexaria remains focused on exploring DehydraTECH’s full potential. So far, it is exploring its potential usage in treating heart disease and hypertension. It is also separately conducting studies on oral nicotine delivery, antiviral delivery, epilepsy, hormone replacement, rheumatoid disease, dementia, and diabetes, most of which will define clinical studies for the 2022 calendar year and beyond.
The company’s management has even noted that the company will continue to see significant milestones in using DehydraTECH, specifically DehydraTECH-CBD, for potential hypertension and heart disease treatment, among other conditions.
“We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” noted Mr. Bunka back in February (https://nnw.fm/rddbO ).
Most notably, Lexaria’s management reckons that clinical studies for 2022 are on schedule and will play an integral role in receiving even more patents for its DehydraTECH technology.
“The approval (by the independent review board earlier this year) sets the stage for the HYPER-H21-4 study that could define Lexaria’s future. DEM-A22-1, expected to begin in July 2022, will evaluate DehydraTECH-CBD with or without nicotine for the potential treatment of dementia. Lexaria also plans to execute on the RHEUM-A22-1 and DIAB-A22-1 studies, scheduled for October and November, respectively…” said Mr. Bunka.
In addition to the 25 granted patents, Lexaria has over 50 pending patents worldwide and is committed to growing its patent portfolio for the benefit of its shareholders, clients, and patients dealing with various conditions that could benefit from its DehydraTECH technology.
“This new patent adds to our existing suite of granted patents in the EU, the U.S., India, Japan, and Australia, and continues to build value for Lexaria shareholders and clients,” Bunka noted.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugs
- This becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S.
- It adds to the company’s growing patent portfolio, which also consists of ~50 pending patents worldwide
- Over the 2022 calendar year, the company seeks to also pursue regulatory and commercial advancement
In 2016, Lexaria Bioscience (NASDAQ: LEXX) received its first United States patent grant and over the years, the company has been aggressive at broadening its patent suite, a move which it has attributed to refining the patent claims via further US provisional and utility patent filings. More patents mean more intellectual property and enhanced ability to pursue regulatory and commercial progress.
As of March 2022, Lexaria had 24 patents, having been granted its latest one in Australia, titled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof” (https://nnw.fm/CYJnV ).
In what marks another significant milestone for Lexaria, it has announced receiving its first-ever patent for the use of DehydraTECH(TM) technology in the enhanced delivery of antiviral drugs. Patent 11,311,559, titled “Compositions and Methods for Enhanced Delivery of Antiviral Agents,” becomes the 10th granted in the U.S.
“This will be our 25th patent granted worldwide and another validation of the versatility of our DehydraTECH drug delivery technology,” noted Lexaria’s Chief Executive Officer (“CEO”), Chris Bunka (https://nnw.fm/F5dID ).
Lexaria had earlier announced and demonstrated how effective remdesivir and ebastine processed with DehydraTECH were against inhibiting COVID-19/SARS-CoV-2. It also separately proved that antiviral drugs processed with DehydraTECH reached peak blood concentration levels that were double those of non-DehydraTECH-processed alternatives. In addition, the company showed that the overall volumes of drugs delivered into the bloodstream were up to triple that of non-DehydraTECH-processed variants.
Lexaria remains focused on exploring DehydraTECH’s full potential. So far, it is exploring its potential usage in treating heart disease and hypertension. It is also separately conducting studies on oral nicotine delivery, antiviral delivery, epilepsy, hormone replacement, rheumatoid disease, dementia, and diabetes, most of which will define clinical studies for the 2022 calendar year and beyond.
The company’s management has even noted that the company will continue to see significant milestones in using DehydraTECH, specifically DehydraTECH-CBD, for potential hypertension and heart disease treatment, among other conditions.
“We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” noted Mr. Bunka back in February (https://nnw.fm/rddbO ).
Most notably, Lexaria’s management reckons that clinical studies for 2022 are on schedule and will play an integral role in receiving even more patents for its DehydraTECH technology.
“The approval (by the independent review board earlier this year) sets the stage for the HYPER-H21-4 study that could define Lexaria’s future. DEM-A22-1, expected to begin in July 2022, will evaluate DehydraTECH-CBD with or without nicotine for the potential treatment of dementia. Lexaria also plans to execute on the RHEUM-A22-1 and DIAB-A22-1 studies, scheduled for October and November, respectively…” said Mr. Bunka.
In addition to the 25 granted patents, Lexaria has over 50 pending patents worldwide and is committed to growing its patent portfolio for the benefit of its shareholders, clients, and patients dealing with various conditions that could benefit from its DehydraTECH technology.
“This new patent adds to our existing suite of granted patents in the EU, the U.S., India, Japan, and Australia, and continues to build value for Lexaria shareholders and clients,” Bunka noted.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼